Prosecution Insights
Last updated: November 11, 2026
Application No. 18/037,592

BIOMARKERS FOR PREDICTING IMMUNOGENICITY AND THERAPEUTIC RESPONSES TO ADALIMUMAB IN RHEUMATOID ARTHRITIS PATIENTS

Non-Final OA §101
Filed
May 18, 2023
Priority
Nov 18, 2020 — SG 10202011473Y +1 more
Examiner
COUNTS, GARY W
Art Unit
1678
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
China Medical University Hospital
OA Round
2 (Non-Final)
59%
Grant Probability
Moderate
2-3
OA Rounds
0m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
498 granted / 844 resolved
-1.0% vs TC avg
Strong +29% interview lift
Without
With
+29.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
42 currently pending
Career history
883
Total Applications
across all art units

Statute-Specific Performance

§101
16.9%
-23.1% vs TC avg
§103
31.6%
-8.4% vs TC avg
§102
10.2%
-29.8% vs TC avg
§112
31.8%
-8.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 844 resolved cases

Office Action

§101
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the claims The amendment filed 07/22/26 is acknowledged and has been entered. Claim 1 has been amended. New claims 27-31 have been added. Claims 21 and 23-26 have been canceled. Claims 10 and 13-19 were previously canceled. Claims 20 and 22 remain withdrawn as being directed to non-elected inventions. Accordingly, claims 1-9, 11-12 and 27-31 are under examination. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-9, 11-12 and 27-31 are rejected under 35 U.S.C. 101 because the claimed invention is directed to abstract ideas and/or to laws of nature/natural phenomena without significantly more. The U.S. Patent and Trademark Office recently revised the MPEP with regard to § 101 (see the MPEP at 2106). Regarding the MPEP at 2106, in determining what concept the claim is “directed to,” we first look to whether the claim recites: (1) any judicial exceptions, including certain groupings of abstract ideas (i.e., mathematical concepts, certain methods of organizing human activity such as a fundamental economic practice, or mental processes); and (2) additional elements that integrate the judicial exception into a practical application (see MPEP § 2106.05(a)-(c), (e)-(h)). Only if a claim (1) recites a judicial exception and (2) does not integrate that exception into a practical application, do we then look to whether the claim contains an “‘inventive concept’ sufficient to ‘transform’” the claimed judicial exception into a patent-eligible application of the judicial exception. Alice, 573 U.S. at 221 (quoting Mayo, 566 U.S. at 82). In so doing, we thus consider whether the claim: (3) adds a specific limitation beyond the judicial exception that is not “well-understood, routine, conventional” in the field (see MPEP § 2106.05(d)); or (4) simply appends well-understood, routine, conventional activities previously known to the industry, specified at a high level of generality, to the judicial exception. See MPEP 2106. ELIGIBILITY STEP 2A: WHETHER A CLAIM IS DIRECTED TO A JUDICIAL EXCEPTION Step 2A, Prong 1 The claims are directed to a naturally occurring correlation between autoantibodies in a serum or plasma sample of a rheumatoid arthritis patient prior to treatment with adalimumab and the patient having a good response or a poor response. Step 2A, Prong 2 The additional elements of testing the sample for autoantibodies to SSB, TROVE2 and ZHX2 by use of an antigen array wherein the antigens are biotinylated and each antigen being formed from a biotin carboxyl carrier protein does not apply, rely on, or use the judicial exception in a manner that imposes a meaningful limit on the judicial exception. Also, with respect to the recitation “making a determination whether the patient will develop a good response or a bad poor response to treatment with adalimumab, based on the detection of said autoantibody biomarkers; wherein said autoantibody biomarkers comprise autoantibodies to antigens SSB, TROVE2 and ZHX2, wherein ZHX2 is associated with the good response, and SSB and TROVE2 are associated with the poor response”. The “determining” statement at best articulates the judicial exception, amounting only to a general instruction to apply or use the judicial exception. This could read on mental activity being performed solely in a practitioner’ head, e.g. A mental appreciation of the recited autoantibodies being correlated a good response or a poor response to adalimumab treatment in the subject. No active method steps are invoked or clearly required; the “determining” statement does not include any activity that would constitute a practical application, i.e. steps that apply, rely on or use the natural principle in a manner such that the claims amount to significantly more that the natural principal itself. ELIGIBILITY STEP 2B: WHETHER THE ADDITIONAL ELEMENTS CONTRIBUTE AN "INVENTIVE CONCEPT" Further, the additional elements of the claims are recited with a high level of generality and do not apply, rely on, or use the judicial exception in a manner that imposes a meaningful limit on the judicial exception. (the active method steps/limitations recited in addition to the judicial exceptions themselves) and do not add significantly more to the judicial exception(s). As shown by ImmuneTM (submitted in the IDS filed 08/29/23) it is well known, routine and conventional in the art to test a sample for autoantibodies to SSB, TROVE2 and ZHX2 and also additional autoantibody biomarkers (e.g. pages 1, 42, 46, 48). ImmneTM also shows that it is well known, routine and conventional to provide an antigen array comprising a panel of biotin carboxyl carrier protein. With respect to the recitation “administering adalimumab to the patient if the determination is that the patient will develop the good response” as recited in instant claim 1. Although the claim invokes administering adalimumab to the patient, the claim currently recites “if the determination is that the patient will develop the good response”. The recitation of “if” allows for the scenario of the determination of a bad response in the patient and thus allows for an embodiment wherein no adalimumab is administered. Therefore, this scenario does not recite something significantly more than the judicial exception. It does not appear to be the case that the active steps recited, which are performed in order to gather the data or perform the assay, are steps recited or performed in an unconventional or non-routine way, such to provide an inventive concept under step 2B. The claimed limitations as currently presented fail to recite limitations that add a feature that is more than well understood, conventional or routine in the field of diagnostics and biochemical assay methodologies. For all of these reasons, the claims fail to include additional elements that are sufficient to either integrate the judicial exception(s) into practical application(s) thereof, or amount to significantly more than the judicial exception(s). Response to Arguments Applicant's arguments filed 07/22/26 have been fully considered but they are not persuasive. 101 Rejection: Applicant argues that Claim 1 has been amended to further comprise "administering adalimumab to the patient if the determination is that the patient will develop the good response." Applicant submits that this reflects an active step that does not rely on or use the alleged natural principle. This argument is not found persuasive because although the claim invokes administering adalimumab to the patient, the claim currently recites “if the determination is that the patient will develop the good response”. The recitation of “if” allows for the scenario of the determination of a bad response in the patient and thus allows for an embodiment wherein no adalimumab is administered. Therefore, this scenario does not recite something significantly more than the judicial exception. The claim does not positively determine the patient will have a good response and then administer the adalimumab to the patient determined to have a good response. Applicant argues that new claims 27-31 recites the action of "providing an antigen array comprising a panel of biotinylated antigens bound to one or more streptavidin-coated substrates, each biotinylated antigen being formed from a Biotin Carboxyl Carrier Protein folding marker which is fused in-frame with an antigen; wherein the antigens comprise SSB, TROVE2, and ZHX2." This argument is not found persuasive because these limitations are considered to be additional elements and do not apply, rely on, or use the judicial exception in a manner that imposes a meaningful limit on the judicial exception. (the active method steps/limitations recited in addition to the judicial exceptions themselves) and do not add significantly more to the judicial exception(s). Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GARY W COUNTS whose telephone number is (571)272-0817. The examiner can normally be reached M-F 7:00-4:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gregory Emch can be reached at 571-272-8149. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GARY COUNTS/ Primary Examiner, Art Unit 1678
Read full office action

Prosecution Timeline

May 18, 2023
Application Filed
Apr 23, 2026
Non-Final Rejection mailed — §101
Jul 22, 2026
Response Filed
Aug 27, 2026
Final Rejection mailed — §101
Oct 27, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12761214
IMMUNOCHROMATOGRAPHY
4y 3m to grant Granted Oct 13, 2026
Patent 12761226
METHOD AND KIT FOR THE EARLY DETECTION OF SEPSIS
3y 10m to grant Granted Oct 13, 2026
Patent 12748111
METHODS FOR DETECTION OF PATHOGENIC ANTIPHOSPHOLIPID ANTIBODIES AND FOR IDENTIFICATION OF INHIBITORS
4y 3m to grant Granted Sep 29, 2026
Patent 12736543
ANTIGEN FOR 2019 NOVEL CORONAVIRUS AND DETECTION USE THEREOF
4y 0m to grant Granted Sep 15, 2026
Patent 12736536
NOVEL CANCER BIOMARKER IN PANCREATIC CANCER OR MALIGNANT INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM
3y 7m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
59%
Grant Probability
88%
With Interview (+29.4%)
3y 1m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 844 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month